Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.42B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.51M
Average 1.21M
AMLX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $21.31M rose 31.8% year over year, ahead of the +15.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at -20.9% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $119.02K (-99.8%) for the fiscal year ending Dec 2026, a slowdown from the -45.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $21.31M-2.8% QoQ
- Last fiscal yearDec 2025
- $62.89M-45.0% YoY
- LTMSep 2026
- $74.79M+15.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 62.89M USD
- Year-over-year change
- -45.0%
- 4-year CAGR
- +12.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.89M | -45.0% |
| FY2024 | 2024-12-31 | 114.33M | -39.3% |
| FY2023 | 2023-12-31 | 188.36M | +48.2% |
| FY2022 | 2022-12-31 | 127.13M | +226.5% |
| FY2021 | 2021-12-31 | 38.93M | — |
Selling, General & Admin vs competitors
How AMLX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.8% is the 4th highest of 10, against a peer median of +10.2%.
- Over three fiscal years its annual growth of -20.9% compares with a peer median of +2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $584.98M USD | +66.3% | +37.9% | 61.0% | |
| LTM Jun 2026 | $139.03M USD | +19.2% | +2.4% | 3857.6% | |
| LTM Sep 2026 | $117.61M USD | +115.1% | -0.3% | — | |
| LTM Sep 2026 | $74.79M USD | +15.8% | -20.9% | — | |
| LTM Mar 2026 | $54.46M USD | -19.1% | +6.0% | 94.0% | |
| LTM Mar 2026 | $16.54M USD | -15.6% | +10.2% | — | |
| LTM Dec 2025 | $12.8M USD | +10.2% | +1.9% | — | |
| LTM Mar 2026 | CHF 11.38M CHF | +4.4% | +6.7% | 307.5% | |
| LTM Mar 2026 | $7.9M USD | -34.1% | -17.0% | 5897.0% | |
| LTM Jun 2026 | $7.78M USD | +11.4% | -90.2% | — | |
| Peer median (excluding AMLX) | — | +10.2% | +2.4% | 307.5% | |
Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 22.23M | 380.79M | 87.37M | 0 |
| Cost of Revenue | 0 | 2.99M | 25.44M | 42.16M | 525K |
| Gross Profit | 0 | 19.24M | 355.35M | 45.22M | (525K) |
| Gross Margin | — | 86.5% | 93.3% | 51.8% | — |
| Research & Development | 44.04M | 93.45M | 128.19M | 104.08M | 90.4M |
| Selling, General & Admin | 38.93M | 127.13M | 188.36M | 114.33M | 62.89M |
| Operating Expenses | 82.69M | 220.58M | 316.54M | 359.95M | 152.77M |
| Depreciation & Amortization | 52K | 487K | 1.09M | 904K | 525K |
| EBITDA | (87.88M) | (197.11M) | 55.39M | (290.98M) | (144.16M) |
| EBITDA Margin | — | -886.7% | 14.5% | -333.0% | — |
| Operating Income | (82.69M) | (201.34M) | 38.8M | (314.73M) | (153.29M) |
| Operating Margin | — | -905.7% | 10.2% | -360.2% | — |
| Interest Income | 36K | 4.29M | 16.16M | 13.81M | 9.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (5.24M) | 3.74M | 15.5M | 12.6M | 8.6M |
| Income Before Tax | (87.93M) | (197.6M) | 54.3M | (302.14M) | (144.69M) |
| Pre-Tax Margin | — | -888.9% | 14.3% | -345.8% | — |
| Income Tax Expense | 0 | 774K | 5.03M | (393K) | 46K |
| Net Income | (87.93M) | (198.38M) | 49.27M | (301.74M) | (144.74M) |
| Net Margin | — | -892.4% | 12.9% | -345.4% | — |
| EPS (Basic) | (1.52) | (2.98) | 0.73 | (4.43) | (1.53) |
| EPS (Diluted) | (1.52) | (2.98) | 0.70 | (4.43) | (1.53) |
| Weighted Avg Shares | 57.86M | 66.51M | 67.23M | 68.14M | 94.57M |
| Weighted Avg Shares (Diluted) | 57.86M | 66.51M | 69.99M | 68.14M | 94.57M |
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
Intrinsic Alpha fair value
Locked
Current Price
$26.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.